28th Mar 2022 07:21
(Alliance News) - AstraZeneca PLC said on Monday that its Evusheld antibody combination for Covid-19 prevention has been granted marketing authorization in the EU.
The Cambridge, England-based pharmaceutical company said the antibody combination was approved for the prevention of Covid-19 in people aged 12 years and above who weigh at least 40 kilograms.
The approval was based on results from the Evusheld clinical development programme, AstraZeneca explained. This included data from the Provent phase three pre-exposure prophylaxis trial, which demonstrated a 77% reduction in the risk of developing symptomatic Covid compared to a placebo.
Evusheld is authorized for emergency use for the prevention of Covid-19 in the US, and has been granted conditional marketing authorization by the Medicines & Healthcare products Regulatory Agency in the UK for the same aim.
Shares in AstraZeneca were up 0.3% at 9,872.00 pence on Monday morning in London.
By Heather Rydings; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca